Target Price | $408.00 |
Price | $343.22 |
Potential | 18.87% |
Number of Estimates | 38 |
38 Analysts have issued a price target Visa 2026 . The average Visa target price is $408.00. This is 18.87% higher than the current stock price. The highest price target is $446.25 30.02% , the lowest is $307.25 10.48% . | |
A rating was issued by 44 analysts: 35 Analysts recommend Visa to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Visa stock has an average upside potential 2026 of 18.87% . Most analysts recommend the Visa stock at Purchase. |
39 Analysts have issued a sales forecast Visa 2025 . The average Visa sales estimate is $40.7b . This is 4.59% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $42.1b 8.19% , the lowest is $38.8b 0.22% .
This results in the following potential growth metrics:
2024 | $35.9b | 10.02% |
---|---|---|
2025 | $40.7b | 13.23% |
2026 | $45.1b | 10.76% |
2027 | $49.6b | 10.14% |
2028 | $54.1b | 9.10% |
29 Analysts have issued an Visa EBITDA forecast 2025. The average Visa EBITDA estimate is $28.5b . This is 5.34% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $29.7b 9.98% , the lowest is $25.6b 5.46% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $25.1b | 9.71% |
---|---|---|
2025 | $28.5b | 13.53% |
2026 | $31.8b | 11.64% |
2027 | $35.1b | 10.49% |
2028 | $38.4b | 9.26% |
2029 | $42.5b | 10.77% |
2024 | 69.84% | 0.28% |
---|---|---|
2025 | 70.02% | 0.26% |
2026 | 70.58% | 0.80% |
2027 | 70.81% | 0.33% |
2028 | 70.91% | 0.14% |
40 Visa Analysts have issued a net profit forecast 2025. The average Visa net profit estimate is $22.5b . This is 12.32% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $23.4b 16.84% , the lowest is $21.4b 6.78% .
This results in the following potential growth metrics and future Net Margins:
2024 | $19.5b | 14.53% |
---|---|---|
2025 | $22.5b | 15.80% |
2026 | $25.3b | 12.30% |
2027 | $28.6b | 12.99% |
2028 | $32.6b | 14.18% |
2029 | $36.9b | 13.07% |
2024 | 54.16% | 4.09% |
---|---|---|
2025 | 55.39% | 2.27% |
2026 | 56.16% | 1.39% |
2027 | 57.61% | 2.58% |
2028 | 60.29% | 4.65% |
40 Analysts have issued a Visa forecast for earnings per share. The average Visa EPS is $11.67 . This is 13.85% higher than earnings per share in the financial year 2024. The highest EPS forecast is $12.14 18.44% , the lowest is $11.09 8.20% .
This results in the following potential growth metrics and future valuations:
2024 | $9.58 | 17.69% |
---|---|---|
2025 | $11.67 | 21.82% |
2026 | $13.10 | 12.25% |
2027 | $14.81 | 13.05% |
2028 | $16.90 | 14.11% |
2029 | $19.11 | 13.08% |
Current | 33.48 | 12.31% |
---|---|---|
2025 | 29.41 | 12.17% |
2026 | 26.19 | 10.95% |
2027 | 23.18 | 11.49% |
2028 | 20.30 | 12.42% |
2029 | 17.96 | 11.53% |
Based on analysts' sales estimates for 2025, the Visa stock is valued at an EV/Sales of 16.40 and an P/S ratio of 16.26 .
This results in the following potential growth metrics and future valuations:
Current | 17.15 | 8.89% |
---|---|---|
2025 | 16.40 | 4.36% |
2026 | 14.81 | 9.71% |
2027 | 13.45 | 9.21% |
2028 | 12.32 | 8.34% |
Current | 17.00 | 8.71% |
---|---|---|
2025 | 16.26 | 4.39% |
2026 | 14.68 | 9.71% |
2027 | 13.32 | 9.21% |
2028 | 12.21 | 8.34% |
Analyst | Rating | Action | Date |
---|---|---|---|
Macquarie |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 30 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Jul 30 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Jul 17 2025 |
Deutsche Bank |
➜
Buy
|
Unchanged | Jul 17 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 02 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Macquarie:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 30 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Jul 30 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Jul 17 2025 |
Unchanged
Deutsche Bank:
➜
Buy
|
Jul 17 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.